In late 2025 and throughout 2026, the White House rolled out a series of landmark executive actions, Medicare rule changes, and direct pharmaceutical negotiations aimed at drastically lowering out-of-pocket costs for GLP-1 medications like Ozempic, Wegovy, and Zepbound. The administration's victory lap included launching direct-to-consumer cost-reduction platforms and pressuring drug manufacturers to expand access for millions of Americans suffering from obesity and metabolic disease.
Yet, whenever President Donald Trump steps up to a podium to talk about one of the most significant pharmaceutical breakthroughs of the century, he rarely uses terms likesemaglutide, tirzepatide, or metabolic health.
Instead, he defaults to a signature blend of populist bluntness and ribbing, routinely referring to GLP-1s as "fat shots," "fat drugs," or "the fat pill."
This stark divide between high-stakes healthcare policy and crude rally rhetoric highlights a classic hallmark of the Trump presidency, distilling complex systemic reform into unvarnished, everyday soundbites.
The Policy | Bringing Down the Cost of GLP-1s
On paper, the administration's strategy around GLP-1 weight-loss and diabetes drugs is one of its most aggressive healthcare initiatives. Driven by rising national rates of cardiovascular disease and skyrocketing healthcare expenditures, executive policy has focused heavily on pricing transparency and direct price capping.
The Dual-Track GLP-1 Strategy
[ The Dual-Track GLP-1 Strategy ]
│
┌────────────────────────────────┴────────────────────────────────┐
▼ ▼
[ The Policy Track ] [ The Rhetorical Track ]
• Direct negotiation with Eli Lilly & Novo Nordisk • Blunt labeling ("fat shots", "fat pills")
• Expanded Medicare & Medicaid coverage rules • Simplification over medical jargon
• Capped monthly copays via federal platforms • Public ribbing of staff & acquaintancesGLP-1 Policy | Key Actions
| Direct Negotiations | Federal health officials pressed Eli Lilly and Novo Nordisk to lower list prices for high-demand GLP-1 therapies in exchange for expanded access across federal healthcare channels. |
| Expanded Coverage | The administration pushed to broaden Medicare and Medicaid rules, allowing coverage for weight-loss medications when prescribed to manage secondary chronic conditions like hypertension, sleep apnea, and heart disease. |
| TrumpRx Capping | By leveraging direct-to-consumer distribution models, out-of-pocket costs for qualified patients were slashed from over $1,000 a month down to targeted copays as low as $150 to $350 per month. |
The Rhetoric | Demystification, Stigma, and Soundbites
While health officials frame GLP-1s as essential clinical interventions for chronic disease management, Trump's public presentation is radically different.
Rhetorical Tactics
Stripping Away Medical Jargon
Terms like "GLP-1 receptor agonist" do not easily register in a television soundbite or at a crowded rally. By calling the medication "the fat drug," Trump strips away technical jargon, instantly signaling to voters what the drug does without relying on medical euphemisms.
The Blunt Populist Persona
Throughout his career in business and politics, Trump has weaponized politically incorrect language to project an image of authentic "straight talk." Where traditional politicians use sanitized language to avoid offending specific demographics, Trump leans into taboo terminology, framing it as calling things by their plain name.
Public Ribbing as a Political Tool
During press briefings and ceremonial bill signings, Trump frequently pairs policy updates with jokes aimed at staff members or public figures in attendance, asking them openly if they are taking "the fat shot." The banter turns a clinical topic into lighthearted entertainment, keeping audience attention locked on the economic accomplishment.
The Dual Public Reaction
Medical & Public Health Critics
Labeling life-saving metabolic drugs "fat shots" trivializes a severe medical condition, reinforces toxic social stigma around obesity, and may deter embarrassed patients from seeking needed treatment.
Administration Supporters
The President is cutting through corporate "Big Pharma" spin to deliver real price relief on a drug millions want, using unfiltered, relatable language that average Americans actually speak.
While medical ethicists and public health advocates cringe at the vocabulary, the administration's pragmatic results remain undeniable for millions of patients accessing discounted GLP-1 prescriptions. Donald Trump may call them "fat drugs," but by making them drastically cheaper, his policy wins are reshaping American healthcare access all the same.
OnyxTimes will continue to track the intersection of healthcare policy and political rhetoric. For related coverage of the administration's health agenda, see our reports on the childhood vaccine executive order and the Wisconsin measles outbreak.